Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H (HK:2315) has released an update.
Biocytogen Pharmaceuticals has entered into a lucrative option and license agreement with IDEAYA Biosciences for a potential first-in-class cancer treatment, with the deal potentially worth up to $406.5 million. The treatment targets multiple solid tumor types and could be integrated with IDEAYA’s existing pipeline, including their DNA Damage Repair therapies. A development candidate for this program is expected by the second half of 2024.
For further insights into HK:2315 stock, check out TipRanks’ Stock Analysis page.
